Compounds according to formula, in which HET is wherein R 2 is selected from among -H, -C 1 -C 4 -alkyl, and -O-C 1 -C 4 -alkyl; wherein R 3 is selected from among -H, -methyl, -ethyl, -propyl, -i-propyl, -cyclopropyl, -OCH 3, and -CN; wherein R 4 and R 5 are independently selected from among -H, and a group of the structure -C 1 -C 6 -alkyl, and wherein R 4 and R 5 if different from -H are optionally independently substituted with one or more groups selected from among -halogen, -OH, -CF 3, and -CN; or wherein R 4 and R 5 are independently selected from among -H, and a group of the structure -L 1 -R 13 wherein L 1 is selected from among -NH- and -N(C 1 -C 4 -alkyl)-, wherein R 13 is -C 3 -C 8 -heterocyclyl, wherein R 13 is optionally substituted by one or more groups selected from among halogen, -CF 3, -OCF 3, -CN, -OH, -O-C 1 -C 4 -alkyl, -C 1 -C 6 -alkyl; or wherein R 4 and R 5 are independently selected from among -H, -CONH 2, and a group selected from among -NR 8 R 9, and -N(R 10,R 10'), wherein R 8, R 9, are independently selected from among -H, -C 1 -C 6 -alkyl, and a group of the structure -C 3 -C 6 -cycloalkyl, wherein such ring is optionally substituted by one or more groups selected from among -F, and -OCH 3, and wherein R 10 and R 10', together form a -C 2 -C 6 -alkylene group such that a ring is formed, wherein such ring is optionally substituted with one or more groups selected from among -OH, -OCH 3, -CF 3, -OCF 3, -CN, -halogen, -C 1 -C 4 -alkyl, =O, and -N(C 0 -C 3 -alkyl)-SO 2 -C 1 -C 3 -alkyl, or wherein R 10 and R 10, together form a -C 2 -C 6 -alkylene group such that a ring is formed, wherein such ring is optionally substituted by the group -C 5 -C 10 -aryl, wherein such -C 5 -C 10 -aryl ring is optionally substituted by a group of the structure -C 0 -C 4 -alkylene-COOH; or wherein R 4 and R 5 are independently selected from -H, and a group selected from among -N(R 11,R 11'), and wherein R 11 and R 11' together form a -C 2 -C 6 -alkylene group such that a ring is formed, in which one ore two carbon centers of the -C 2 -C 6 -alkylene group may optionally be replaced by one or two hetero atoms selected from among N, O, and S, wherein such ring is optionally be substituted by one or more groups on one ring atom or on two neighbouring ring atoms selected from among -OH, -NH 2, -C 1 -C 3 -alkyl, -O-C 1 -C 6 -alkyl, -CN, -CF 3, -OCF 3, =O, and halogen; as well as in form of their acid addition salts with pharmacologically acceptable acids. wherein R 2 is selected from among -H, -C 1 -C 4 -alkyl, and -O-C 1 -C 4 -alkyl; wherein R 3 is selected from among -H, -methyl, -ethyl, -propyl, -i-propyl, -cyclopropyl, -OCH 3, and -CN; wherein R 4 and R 5 are independently selected from among -H, and a group of the structure -C 1 -C 6 -alkyl, and wherein R 4 and R 5 if different from -H are optionally independently substituted with one or more groups selected from among -halogen, -OH, -CF 3, and -CN; or wherein R 4 and R 5 are independently selected from among -H, and a group of the structure -L 1 -R 13 wherein L 1 is selected from among -NH- and -N(C 1 -C 4 -alkyl)-, wherein R 13 is -C 3 -C 8 -heterocyclyl, wherein R 13 is optionally substituted by one or more groups selected from among halogen, -CF 3, -OCF 3, -CN, -OH, -O-C 1 -C 4 -alkyl, -C 1 -C 6 -alkyl; or wherein R 4 and R 5 are independently selected from among -H, -CONH 2, and a group selected from among -NR 8 R 9, and -N(R 10,R 10'), wherein R 8, R 9, are independently selected from among -H, -C 1 -C 6 -alkyl, and a group of the structure -C 3 -C 6 -cycloalkyl, wherein such ring is optionally substituted by one or more groups selected from among -F, and -OCH 3, and wherein R 10 and R 10', together form a -C 2 -C 6 -alkylene group such that a ring is formed, wherein such ring is optionally substituted with one or more groups selected from among -OH, -OCH 3, -CF 3, -OCF 3, -CN, -halogen, -C 1 -C 4 -alkyl, =O, and -N(C 0 -C 3 -alkyl)-SO 2 -C 1 -C 3 -alkyl, or wherein R 10 and R 10, together form a -C 2 -C 6 -alkylene group such that a ring is formed, wherein such ring is optionally substituted by the group -C 5 -C 10 -aryl, wherein such -C 5 -C 10 -aryl ring is optionally substituted by a group of the structure -C 0 -C 4 -alkylene-COOH; or wherein R 4 and R 5 are independently selected from -H, and a group selected from among -N(R 11,R 11'), and wherein R 11 and R 11' together form a -C 2 -C 6 -alkylene group such that a ring is formed, in which one ore two carbon centers of the -C 2 -C 6 -alkylene group may optionally be replaced by one or two hetero atoms selected from among N, O, and S, wherein such ring is optionally be substituted by one or more groups on one ring atom or on two neighbouring ring atoms selected from among -OH, -NH 2, -C 1 -C 3 -alkyl, -O-C 1 -C 6 -alkyl, -CN, -CF 3, -OCF 3, =O, and halogen; as well as in form of their acid addition salts with pharmacologically acceptable acids.